RJA
VRDN icon

Raymond James & Associates’s Viridian Therapeutics VRDN Stock Holding History

Raymond James & Associates’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$509K Buy
22,395
+10,955
+96% +$179K ﹤0.01% 3100
2024
Q2 		$149K Sell
11,440
-109
-0.9% -$1.51K ﹤0.01% 3669
2024
Q1 		$202K Buy
11,549
+1,321
+13% +$25.6K ﹤0.01% 3611
2023
Q4 		$223K Sell
10,228
-4,936
-33% -$77.9K ﹤0.01% 3460
2023
Q3 		$233K Buy
15,164
+6,303
+71% +$120K ﹤0.01% 3380
2023
Q2 		$211K Sell
8,861
-278
-3% -$7.13K ﹤0.01% 3456
2023
Q1 		$232K Buy
+9,139
New +$293K ﹤0.01% 3408
2018
Q4 		– Sell
-1,495
Closed -$125K – 3705
2018
Q3 		$125K Buy
1,495
+88
+6% +$8.3K ﹤0.01% 3402
2018
Q2 		$135K Buy
+1,407
New +$149K ﹤0.01% 3352

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Raymond James & Associates's VRDN Position: Q3 2024 in Review

Raymond James & Associates increased its Viridian Therapeutics (VRDN) stake by 96% in Q3 2024, buying an estimated $179K and bringing the position to 22,395 shares worth $509K. The position accounts for ﹤0.01% of the portfolio, ranked #3100.

Raymond James & Associates first reported a position in VRDN in Q2 2018 and has held it in 9 quarters since. 165 funds tracked by Wall St. Rank hold VRDN as of Q3 2024.

  • Raymond James & Associates held 22,395 shares of Viridian Therapeutics worth $509K as of Q3 2024.
  • Raymond James & Associates bought 10,955 Viridian Therapeutics shares in Q3 2024, an estimated $179K.
  • Viridian Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3100 holding.
  • Raymond James & Associates first reported a position in Viridian Therapeutics in Q2 2018 and has held it in 9 quarters since.
  • 165 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.